Orano in the news

Orano Med opened a 25 million euro laboratory in Valenciennes to produce lead-212 for targeted alpha therapy, aiming to address radioisotope shortages and deliver cancer treatments across Europe.

Orano is partnering with Assystem to urbanize the Construction Information System for its Future Downstream project, aiming to define and implement the SI throughout the construction period.

Orano Med inaugurated its ATLab Valenciennes, Europe's first industrial-scale facility for lead-212 radioligand therapies, to produce up to 10,000 doses per year for cancer treatment.

Orano Med opened a new ATlab in Valenciennes to produce alpha-radiotherapy cancer drugs using lead-212, with clinical production starting in 2027.

Orano's Aval du futur project will create 10,000 jobs in La Hague, prompting Saint-Lô Agglo and other local entities to collaborate on managing the impact.

Orano inaugurated a lead-212 production facility in Valenciennes, France, to produce up to 10,000 annual doses of targeted alpha therapy for cancer treatment, addressing supply shortages.

Orano Med opened Europe's first alpha-therapy factory near Valenciennes, France, to produce lead-212 cancer treatments, with an investment of  29 million.

Orano Med invested 29 million euros in a new ATLab facility in Northern France for large-scale production of targeted alpha therapies with Lead-212.

Orano Tricastin hosted an open day for employees' families to showcase their work environment, fulfilling a request from internal discussions.

Fatima-Ezzahra El Mansouri becomes Morocco's first female government head, Sahelian juntas unite at the UN, Niger seeks new uranium investors amid Orano disputes, and "Mission 300" aims to electrify rural Africa with solar.

Orano MED is building a new factory in Onnaing, France, to produce an innovative lead-212-based cancer drug, with plans to supply 70% of the European market following clinical trials and regulatory approval.

Orano Med opened a 29 million euro industrial site in Valenciennes, France, for large-scale production of lead-212 targeted alpha therapies for cancer treatment, supported by France 2030.

Local residents are protesting a potential Orano facility on agricultural land in Yvetot-Bocage, even though Orano has not yet made a final decision.

Orano Med has inaugurated ATLab, an industrial facility in Valenciennes, to produce lead-212 targeted alpha-radiotherapies for cancer, with an investment of 29 million euros and a strategic location for rapid European distribution.

Orano's proposed temporary logistics platform in Yvetot-Bocage for nuclear material transport faces local opposition over environmental concerns and lack of communication, prompting the company to reassess its plans and reduce its footprint.

Orano is opening a new site in Bordeaux, France, to recruit engineers for its "L'aval du futur" nuclear project, estimated at 40 billion euros over 20 years.

Orano will begin 1.5 million euro compensatory work for wetlands destruction near its La Hague site on October 5, 2026, due to regulatory obligations for future construction.